DS18561882 (oral administration; 30, 100 or 300 mg/kg; twice daily) inhibits tumor growth inhibition with a dose-dependent manner, the tumor is completely inhibited (TGI: 67%) at the dose of 300 mg/kg in mice.
DS18561882 (oral administration; 10, 30, 100, or 300 mg/kg) has a good oral pharmacokinetic profile, including ACU (64.6, 264, 726 μg.h/ml ); Cmax (11.4, 56.5, 90.1 μg/ml); t1/2 (2.21, 2.16, 2.32 hours) for 30 mg/kg; 100mg/kg; 200 mg/kg, respectively.
DS18561882 is suspended in a 0.5% (w/v) methyl cellulose 400 solution in this article.
Animal Model: |
Five week old female BALB/cAJcl-nu/nu mice with MDA-MB-231 luc tumor cells (4 × 10 cells/mouse) |
Dosage: |
30, 100 or 300 mg/kg |
Administration: |
Oral administration; 30, 100 or 300 mg/kg; twice daily; until day 11 |
Result: |
Suppressed tumor growth in a dose-dependent manner. |